Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > The big dogs have to eat.......

<< Previous

Bullboard Posts

Next >>

Comment by RalphRalphon Feb 17, 2021 6:17pm

246 Views

Post# 32591333

RE:The big dogs have to eat.......

Canaccord involvement itself is not overly impressive. The fact that the deal with Canaccord came with warrants speaks volumes. What Antibe really needs to get to the next level - and why they need to uplist to the NASDAQ asap - is biotech focused fund backing: buying from Perceptive, RTW, Avoro, Baker, BVF, etc.

deadpatient wrote: Cannacord is one of the main reasons we're at seven today.....This is part of a well laid out plan , Institutional shareholders was the cry,well their here now. Relax a couple of soft days will not derail this awakening monster

<< Previous

Bullboard Posts

Next >>

Pro Women’s Hockey League comes to NHL 25 in December